# INFevo

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/infevo

- Industry: Biotechnology
- Headquarters: Beijing, China
- Latest round: Angel (Jun 1, 2026)
- Investors on record: 3

## About

Based in Beijing, China and founded in 2025, Beijing Infinite Evolution Technology Co., Ltd., dba INFevo, was established as an internally incubated project of XtalPi Inc. The company focuses on applying AI and system biology approaches to support drug research and development, leveraging interdisciplinary expertise in biology, data science, and engineering. In June 2026, INFevo closed Angel funding from Shunwei Capital, HSG, Green Pine Capital Partners.

The company develops AI-based virtual cell models and integrates them with automated experimental platforms to support biological research and drug discovery. Its platform combines proprietary foundation models with cellular-level simulations and system biology analysis to enable target discovery, virtual drug screening, and clinical research optimization. The solutions are applied in research areas including aging, neurodegenerative diseases, autoimmune diseases, metabolic disorders, and oncology, supporting both early-stage discovery and translational research.

The company generates revenue from AI-driven drug discovery services, research platform collaborations with pharmaceutical and biotechnology partners, and related data and technology solutions.

## Funding rounds

- Angel, Jun 1, 2026 — Green Pine Capital Partners, Shunwei Capital, HSG

## Investors

- Green Pine Capital Partners (https://capitalatlas.ai/funds/green-pine-capital-partners) — Angel
- Shunwei Capital (https://capitalatlas.ai/funds/shunwei-capital) — Angel
- HSG (https://capitalatlas.ai/funds/hsg) — Angel